Chimeric Therapeutics

JENNIFER CHOW

CEO

(ASX:CHM)

◾ Company Name: Chimeric Therapeutics ◾ Company ASX code: CHM ◾ Key areas: Biotechnology, cell therapies, CAR-T cell therapy, NK cell therapy ◾ Key Personnel: Jennifer Chow, CEO | Paul Hopper, Chairman | Dr Jason Litten, Chief Medical Officer | Eliot Bourk, Chief Business Officer ◾ Locations: Australia, United States ◾ Market Cap as of 15/09/22: $42.52M ◾ 52 Week share price as of 15 September: $0.085 - $0.342 ◾ Company Website: chimerictherapeutics.com

COMPANY PROFILE

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer. Chimeric believes that cellular therapies have the promise to cure cancer, not just slow its progress.

Traditional oncology therapeutics including chemotherapies and immunotherapies focus on targeting either the host or the tumour with a goal to delay cancer progression. Cellular therapies target both the host and the tumour with the goal to cure cancer not just delay its progression.

This goal to cure cancer has recently been realised as patients treated over a decade ago with CAR-T cell therapies remain cancer free.

The current cell therapy market is valued at US$10 billion and is estimated to reach US$60 billion by 2030. Notable exits have included the Celgene acquisition of Juno for US$9B and the Gilead acquisition of Kite for US$12B.

Chimeric has a diversified portfolio that includes seven next-generation autologous and allogeneic therapies that utilise Natural Killer and T cells. Chimeric assets are being developed across 10+ disease areas in oncology with three current clinical programs and plans to open additional clinical programs in 2023.

Chimeric Antigen Receptor (CAR) T Cell therapies are custom therapies manufactured for each patient. CAR-T cell therapy begins with a patient’s T cells which are enhanced in a lab to find and destroy that patient’s unique cancer.

CHM 1101 is a first in class CLTX CAR-T cell therapy currently in a phase 1 clinical trial for patients with glioblastoma. Chimeric recently reported promising early phase 1 data with CHM 1101 showing ~70% of patients treated in dose cohort 1 and 2 achieved disease stability with no notable adverse events.

CHM 2101 is a first in class CDH17 CAR-T cell therapy currently headed for a phase 1 clinical trial in 2023 in gastrointestinal cancers. The preclinical data for CHM 2101 was published as the cover article in the prestigious Nature Cancer publication and demonstrated complete eradication of tumour cells with no relapse.

Natural Killer (NK) cell therapy utilises healthy donor cells rather than a patient’s own cells. NK cells form part of our immune system and have an innate ability to detect and destroy cells that look abnormal. NK cells can also be genetically modified to enhance their cancer killing ability.

CHM 0201 is a CORE (Clinically validated, Off the shelf, Robust, Enhanced) Natural Killer cell platform. An initial phase 1 clinical study has demonstrated early promise in both solid tumours and blood cancers with one patient having a complete response to CHM 0201 therapy (achieving complete eradication of the cancer) and remaining cancer free more than 15 months after therapy.

Based on the initial positive signals with CHM 0201, a new clinical trial has recently been initiated and is the first-ever trial to explore NK cells (CHM 0201) in combination with Vactosertib and IL2.

Additionally Chimeric is leveraging CHM 0201 to develop four new assets, an enhanced NK platform (CHM 0301) and three novel CAR NK (CHM 1301, 2301 and 3301) assets.

Chimeric has an industry leading team with more than 50 combined years of experience developing and commercialising cell therapies. The team has extensive CAR-T cell therapy experience having worked on four of the six currently approved CAR-T cell therapies.

KEY INVESTMENT HIGHLIGHTS

◾ Early Positive Signals in Multiple Clinical Trials: Positive phase 1 data in Glioblastoma with CHM 1101 and in blood cancers with the CORE NK platform. ◾ Innovative & Diversified Portfolio: Seven novel individualised T cell and off the shelf NK cell therapies in development. ◾ Extensive Clinical Development Plan with a Broad Focus: Development across 10+ types of cancer with three current clinical trials and planned expansion in 2023 ◾ Industry Leading Experience: Internal team of experts in cell therapy development and commercialization.